$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other

Novo 2022 Capital Markets Day Highlights and Analysis

Novo hosted its 2022 Capital Markets Day (presentations) and provided updates on the strategic direction of the company across key commercial and R&D activities. Below, FENIX provides details and insights from the call.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home